Original work

2024

Chen H, Liu L, Wang Y, Hong L, Zhong W, Lehr T, Bragazzi NL, Tang B, Dai H. Burden of cardiovascular disease attributable to metabolic risks in 204 countries and territories from 1990 to 2021. Eur Heart J Qual Care Clin Outcomes. 2024; Oct 23:qcae090. doi: 10.1093/ehjqcco/qcae090. Epub ahead of print. 

Dings C, Selzer D, Bragazzi NL, Möhler E, Wenning M, Gehrke T, Richter E, Nonnenmacher A, Brinkmann F, Rothoeft T, Zemlin M, Lücke T, Lehr T. Effect of vaccinations and school restrictions on the spread of COVID-19 in different age groups in Germany. Infect Dis Model. 2024; 9(4):1250-1264. 

Dings C, Lehr T, Vojnar B, Gaik C, Koch T, Eberhart LHJ, Huljic-Lankinen S, Murst M, Kreuer S. Population kinetic/pharmacodynamic modelling of the haemodynamic effects of cafedrine/theodrenaline (Akrinor) under general anaesthesia. Br J Clin Pharmacol. 2024. doi:10.1111/bcp.16083

Kovar C, Loer HLH, Rüdesheim S, Fuhr LM, Marok FZ, Selzer D, Schwab M, Lehr T. A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions. CPT Pharmacometrics Syst Pharmacol. 2024. doi:10.1002/psp4.13146

Loer HLH, Kovar C, Rüdesheim S, Marok FZ, Fuhr LM, Selzer D, Schwab M, Lehr T. Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions. CPT Pharmacometrics Syst Pharmacol. 2024;00:1-15.

Nunes MC, Thommes E, Fröhlich H, Flahault A, Arino J, Baguelin M, Biggerstaff M, Bizel-Bizellot G, Borchering R, Cacciapaglia G, Cauchemez S, Barbier-Chebbah A, Claussen C, Choirat C, Cojocaru M, Commaille-Chapus C, Hon C, Kong J, Lambert N, Lauer KB, Lehr T, Mahe C, Marechal V, Mebarki A, Moghadas S, Niehus R, Opatowski L, Parino F, Pruvost G, Schuppert A, Thiébaut R, Thomas-Bachli A, Viboud C, Wu J, Crépey P, Coudeville L. Redefining pandemic preparedness: Multidisciplinary insights from the CERP modelling workshop in infectious diseases, workshop report. Infect Dis Model. 2024;9(2):501-518.

Och K, Turki AT, Götz KM, Selzer D, Brossette C, Theobald S, Braun Y, Graf N, Rauch J, Rohm K, Weiler G, Kiefer S, Schwarz U, Eisenberg L, Pfeifer N, Ihle M, Grandjean A, Fix S, Riede C, Rissland J, Smola S, Beelen DW, Kaddu-Mulindwa D, Bittenbring J, Lehr T. A dynamic time‐to‐event model for prediction of acute graft‐versus‐host disease in patients after allogeneic hematopoietic stem cell transplantation. Cancer Med. 2024;13(1):e6833.

Marok FZ, Wojtyniak JG, Selzer D, Dallmann R, Swen JJ, Guchelaar HJ, Schwab M, Lehr T. Personalized chronomodulated 5-fluorouracil treatment: A physiologically-based pharmacokinetic precision dosing approach for optimizing cancer therapy. Clin Pharmacol Ther. 2024;10.1002/cpt.3181.

2023

Sager P, Kaiser A, Schumann S, Ludescher B, Niedermaier M, Schmidt I, Och K, Dings C, Lehr T, Brysch W. Efficacy and safety of MP1032 plus standard-of-care compared to standard-of-care in hospitalised patients with COVID-19: a multicentre, randomised double-blind, placebo-controlled phase 2a trial. Lancet Reg Health Eur. 2023;37:100810.

Rosa Lundbye Allesøe RL, Lundgaard AT, Medina RH, Aguayo-Orozco A, Johansen J, Nissen JN, Brorsson C, Mazzoni G, Niu L, Biel JH, Rodríguez CL, Brasas V, Webel H, Benros ME, Pedersen AG, Chmura PJ, Jacobsen UP, Mari A, Koivula R, Mahajan A, Vinuela A, Tajes JF, Sharma S, Haid M, Hong MG, Musholt PB, De Masi F, Vogt J, Pedersen HK, Gudmundsdottir V, Jones A, Kennedy G, Bell J, Thomas EL, Frost G, Thomsen H, Hansen E, Hansen TH, Vestergaard H, Muilwijk M, Blom MT, ‘t Hart LM, Pattou F, Raverdy V, Brage S, Kokkola T, Heggie A, McEvoy D, Mourby M, Kaye J, Hattersley A, McDonald T, Ridderstråle M, Walker M, Forgie I, Giordano GN, Pavo I, Ruetten H, Pedersen O, Hansen T, Dermitzakis E, Franks PW, Schwenk JM, Adamski J, McCarthy MI, Pearson E, Banasik K, Rasmussen S, Brunak S & IMI DIRECT Consortium. Discovery of drug–omics associations in type 2 diabetes with generative deep-learning models. Nat Biotechnol. 2023;41(3):399-408.

Hüppe T, Götz KM, Meiser A, de Faria Fernandes A, Maurer F, Groesdonk HV, Volk T, Lehr T, Kreuer S. Population pharmacokinetic modeling of multiple-dose intravenous fosfomycin in critically ill patients during continuous venovenous hemodialysis. Sci Rep. 2023;13(1):18132.

Rothoeft T, Brinkmann F, Maier C, Selzer D, Dings C, Kuehn A, Möhler E, Grote H, Nonnenmacher A, Wenning M, Zemlin M, Richter U, Lehr T, Lücke T. Motivations for adolescent COVID-19 vaccination: A comparative study of adolescent and caregiver perspectives in Germany. Children (Basel). 2023;10(12):1890.

Fuhr LM, Marok FZ, Fuhr U, Selzer D, Lehr T. Physiologically based pharmacokinetic modeling of bergamottin and 6,7-dihydroxybergamottin to describe CYP3A4 mediated grapefruit-drug interactions. Clin Pharmacol Ther. 2023;114(2):470-482.

Feick D, Rüdesheim S, Marok FZ, Selzer D, Loer HLH, Teutonico D, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Schwab M, Lehr T. Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug–drug–gene interaction network. CPT Pharmacometrics Syst Pharmacol 2023;00:1-14

Türk D, Scherer N, Selzer D, Dings C, Hanke N, Dallmann R, Schwab M, Timmins P, Nock V, Lehr T. Significant impact of time-of-day variation on metformin pharmacokinetics. Diabetologia 2023.

Loer HLH, Feick D, Rüdesheim S, Selzer D, Schwab M, Teutonico D, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Lehr T. Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions. CPT Pharmacometrics Syst Pharmacol 2023;00:1-15.

Marok FZ, Wojtyniak J-G, Fuhr LM, Selzer D, Schwab M, Weiss J, Haefeli WE, Lehr T. A physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug–drug interaction perpetrators. Pharmaceutics. 2023;15(2):679.

Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401(10374):347-356.

Dawed AY, Mari A, Brown A, McDonald TJ, Li L, Wang S, Hong MG, Sharma S, Robertson NR, Mahajan A, Wang X, Walker M, Gough S, 't Hart LM, Zhou K, Forgie I, Ruetten H, Pavo I, Bhatnagar P, Jones AG, Pearson ER; DIRECT consortium. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. 2023;11(1):33-41.

2022

Kovar C, Kovar L, Rüdesheim S, Selzer D, Ganchev B, Kröner P, Igel S, Kerb R, Schaeffeler E, Mürdter TE, Schwab M, Lehr T. Prediction of drug–drug–gene interaction scenarios of (E)-clomiphene and its metabolites using physiologically based pharmacokinetic modeling. Pharmaceutics 2022;14(12):2604.

Paulus FW, Joas J, Gerstner I, Kühn A, Wenning M, Gehrke T, Burckhart H, Richter U, Nonnenmacher A, Zemlin M, Lücke T, Brinkmann F, Rothoeft T, Lehr T, Möhler E. Problematic internet use among adolescents 18 months after the onset of the COVID-19 pandemic. Children 2022; 9(11):1724.

Hussong J, Möhler E, Kühn A, Wenning M, Gehrke T, Burckhart H, Richter U, Nonnenmacher A, Zemlin M, Lücke T, Brinkmann F, Rothoeft T, Lehr T. Mental health and health-related quality of life in German adolescents after the third wave of the COVID-19 pandemic. Children 2022; 9(6):780.

Dings C, Meiser P, Holzer F, Flegel M, Selzer D, Nagy E, Mösges R, Klussmann JP, Lehr T. Pharmacometric modeling of the impact of azelastine nasal spray on SARS-CoV-2 viral load and related symptoms in COVID-19 patients. Pharmaceutics 2022;14(10):2059.

Dings C, Götz KM, Och K, Sihinevich I, Werthner Q, Smola S, Bliem M, Mahfoud F, Volk T, Kreuer S, Rissland J, Selzer D, Lehr T. Model-based analysis of SARS-CoV-2 infections, hospitalization and outcome in Germany, the federal states and districts. Viruses 2022;14(10):2114.

Sternjakob-Marthaler A, Berkó-Göttel B, Rissland J, Schöpe J, Taurian E, Müller H, Weber G, Lohse S, Lamberty T, Holleczek B, Stoffel H, Hauptmann G, Giesen M, Firk C, Schanzenbach A, Brandt F, Hohmann H, Werthner Q, Selzer D, Lehr T, Wagenpfeil S, Smola S. Human papillomavirus vaccination of girls in the German model region Saarland: insurance data-based analysis and identification of starting points for improving vaccination rates. PLoS ONE 2022;17(9):e0273332.

Rüdesheim S, Selzer D, Mürdter T, Igel S, Kerb R, Schwab M, Lehr T. Physiologically based pharmacokinetic modeling to describe the CYP2D6 activity score-dependent metabolism of paroxetine, atomoxetine and risperidone. Pharmaceutics 2022;14(8):1734.

Fuhr LM, Marok FZ, Mees M, Mahfoud F, Selzer D, Lehr T. A physiologically based pharmacokinetic and pharmacodynamic model of the CYP3A4 substrate felodipine for drug-drug interaction modeling. Pharmaceutics 2022;14(7):1474.

Türk D, Müller F, Fromm MF, Selzer D, Dallmann R, Lehr T. Renal transporter-mediated drug-biomarker interactions of the endogenous substrates creatinine and N1-methylnicotinamide: a PBPK modeling approach. Clin Pharmacol Ther 2022;112(3):687-698.

Müller MA, Scholtes MA, Louis C, Dörje F, Lehr T. Piloterhebung zur Fortbildungssituation der Apotheker*innen in Deutschland. Z Evid Fortbild Qual Gesundh wesen (ZEFQ) 2022;172:78-91.

Loer HLH, Türk D, Gómez-Mantilla JD, Selzer D, Lehr T. Physiologically based pharmakokinetic (PBPK) modeling of clopidogrel and its four relevant metabolites for CYP2B6, CYP2C8, CYP2C19 and CYP3A4 drug-drug-gene interaction predictions. Pharmaceutics 2022;14(5):915.

Rüdesheim S, Selzer D, Fuhr U, Schwab M, Lehr T. Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups. CPT Pharmacometrics Syst Pharmacol 2022;11:494-511.

Kovar L, Wien L, Selzer D, Kohl Y, Bals R, Lehr T. In vitro-in silico modeling of caffeine and diclofenac permeation in static and fluidic systems with a 16HBE lung cell barrier. Pharmaceuticals 2022;15(2):250.

Van De Vyver A, Eigenmann M, Ovacik M, Pohl C, Herter S, Weinzierl T, Fauti T, Klein C, Lehr T, Bacac M, Walz AC. A novel approach for quantifying the pharmacological activity of T-cell engagers utilizing in vitro time course experiments and streamlined data analysis. The AAPS Journal 2022;24(1):7.

Weiss J, Foerster KI, Weber M, Burhenne J, Mikus G, Lehr T, Haefeli WE. Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound? Eur J Pharm Sci 2022;169:106076.

 

2021

Türk D, Fuhr LM, Marok FZ, Rüdesheim S, Kühn A, Selzer D, Schwab M, Lehr T. Novel models for the prediction of drug-gene interactions. Expert Opin on Drug Metab Toxicol 2021;17(11):1293-1310.

Nordmeier F, Sihinevich I, Doerr AA, Walle N, Laschke MW, Lehr T, Menger MD, Schmidt PH, Meyer MR, Schaefer N. Toxicokinetics of U-47700, tramadol, and their main metabolites in pigs following intravenous administration: is a multiple species allometric scaling approach useful for the extrapolation of toxicokinetic parameters to humans? Arch Toxicol 2021;95(12):3681-3693.

Van De Vyver AJ, Marrer-Berger E, Wang K, Lehr T, Walz AC. Cytokine release syndrome by T-cell-redirecting therapies: can we predict and modulate patient risk? Clin Cancer Res 2021;27(22):6803-6094.

Schräpel C, Kovar L, Selzer D, Hofmann U, Tran F, Reinisch W, Schwab M, Lehr T. External model performance evaluation of twelve infliximab population pharmacokinetic models in patients with inflammatory bowel disease. Pharmaceutics 2021;13(9):1368.

Marok FZ, Fuhr LM, Hanke N, Selzer D, Lehr T. Physiologically based pharmacokinetic modeling of bupropion and its metabolites in a CYP2B6 drug-drug-gene interaction network. Pharmaceutics 2021;13(3):331.

Frechen S, Sodolenko J, Wendl T, Dallmann, A Ince I, Lehr T, Lippert J, Burghaus R. A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-SIM and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions. CPT Pharmacometrics Syst Pharmacol 2021;00:1-12.

Kohl Y, Hesler M, Drexel R, Kovar L, Dähnhardt-Pfeiffer S, Selzer D, Wagner S, Lehr T, von Briesen H, Meier F. Influence of physicochemical characteristics and stability of gold and silver nanoparticles on biological effects and translocation across an intestinal barrier - a case study from in vitro to in silico. Nanomaterials 2021;11(6):1358.

Fuhr LM, Marok FZ, Hanke N, Selzer D, Lehr T. Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and its drug-drug interaction potential: a physiologically based pharmacokinetic modeling approach. Pharmaceutics 2021;13(2):270.

Van De Vyver AJ, Weinzierl T, Eigenmann MJ, Frances N, Herter S, Buser RB, Somandin J, Diggelmann S, Limani F, Lehr T, Bacac M, Walz AC. Predicting tumor killing and T-cell activation by T-cell bispecific antibodies as a function of target expression: combining in vitro experiments with systems modeling. Mol Cancer Ther 2021;20(2):357-366.

Wojtyniak JG, Selzer D, Schwab M, Lehr T. Physiologically based precision dosing approach for drug-drug-gene interactions: a simavastatin network analysis. Clin Pharmacol Ther 2021;109(1):201-211.

Müller-Wirtz LM, Maurer F, Brausch T, Kiefer D, Floss M, Doneit J, Volk T, Sessler DI, Fink T, Lehr T, Kreuer S. Exhaled propofol concentrations correlate with plasma and brain tissue concentrations in rats. Anesth Analg 2021;132(1):110-118.

2020

Rüdesheim S, Wojtyniak JG, Selzer D, Hanke N, Mahfoud F, Schwab M, Lehr T. Physiologically based pharmacokinetic modeling of metoprolol enantiomers and α-hydroxymetoprolol to describe CYP2D6 drug-gene interactions. Pharmaceutics 2020;12(12):1200.

Kovar L, Weber A, Zemlin M, Kohl Y, Bals R, Meibohm B, Selzer D, Lehr T. Physiologically-based pharmacokinetic (PBPK) modeling providing insights into fentanyl pharmacokinetics in adults and pediatric patients. Pharmaceutics 2020;12(10):908.

Britz H, Hanke N, Taub ME, Wang T, Prasad B, Fernandez É, Stopfer P, Nock V, Lehr T. Physiologically based pharmacokinetic models of probenecid and furosemide to predict transporter mediated drug-drug interactions. Pharm Res 2020;37:250.

Türk D, Hanke N, Lehr T. A physiologically-based pharmacokinetic model of trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 drug-drug-gene interaction predictions. Pharmaceutics 2020;12(11):1074.

Kovar L, Schräpel C, Selzer D, Kohl Y, Bals R, Schwab M, Lehr T. Physiologically-based pharmacokinetic (PBPK) modeling of buprenorphine in adults, children and preterm neonates. Pharmaceutics 2020;12(6):578.

Hanke N, Türk D, Selzer D, Wiebe S, Fernandez É, Stopfer P, Nock V, Lehr T. A mechanistic, enantioselective, physiologically based pharmacokinetic model of verapamil and norverapamil, built and evaluated for drug-drug interaction studies. Pharmaceutics 2020;12(6):556.

Balazki P, Schaller S, Eissing T, Lehr T. A physiologically-based quantitative systems pharmacology model of the incretin hormones GLP-1 and GIP and the DPP4 inhibitor sitagliptin. CPT Pharmacometrics Syst Pharmacol 2020;9(6):353-362.

Wojtyniak JG, Britz H, Selzer D, Schwab M, Lehr T. Data digitizing: accurate and precise data extraction for quantitative systems pharmacology and physiologically‐based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol 2020;9(6):322-331.

Hanke N, Türk D, Selzer D, Ishiguro N, Ebner T, Wiebe S, Müller F, Stopfer P, Nock V, Lehr T. A comprehensive whole-body physiologically based pharmacokinetic drug-drug-gene interaction model of metformin and cimetidine in healthy adults and renally impaired individuals. Clin Pharmacokinet 2020;59:1419-1431.

Piotrowski A, Meyer M, Burkholder I, Renaud D, Müller MA, Lehr T, Laag S, Meiser J, Manderscheid L, Köberlein-Neu J. Effect of an interprofessional care concept on the hospitalization of nursing home residents: study protocol for a cluster-randomized controlled trial. Trials 2020;21:411.

Fuhr LM, Hanke N, Meibohm B, Lehr T. Effective removal of dabigatran by idarucizumab or hemodialysis: a physiologically based pharmacokinetic modeling analysis. Clin Pharmacokinet 2020;59(6):809-825.

Kovar L, Selzer D, Britz H, Benowitz N, St. Helen G, Kohl Y, Bals R, Lehr T. Comprehensive parent-metabolite PBPK/PD modeling insights into nicotine replacement therapy strategies. Clin Pharmacokinet 2020;59(9):1119-1134.

Mueller MA, Opitz R, Grandt D, Lehr T. The federal standard medication plan in practice: an observational cross-sectional study on prevalence and quality. Res Social Adm Pharm 2020;16(10):1370-1378.

Li X, Frechen S, Moj D, Lehr T, Taubert M, Hsin C, Mikus G, Neuvonen PJ, Olkkola KT, Saari TI, Fuhr U. A physiologically based pharmacokinetic model of voriconazole integrating time-dependent inhibition of CYP3A4, genetic polymorphisms of CYP2C19 and predictions of drug-drug interactions. Clin Pharmacokinet 2020;59(6):781-808.

2019

Volz AK, Dingemanse J, Krause A, Lehr T. Target-mediated population pharmacokinetic modeling of endothelin receptor antagonists. Pharm Res 2019;37(1):2.

Lippert J, Burghaus R, Edginton A, Frechen S, Karlsson M, Kovar A, Lehr T, Milligan P, Nock V, Ramusovic S, Riggs M, Schaller S, Schlender J, Schmidt S, Sevestre M, Sjögren E, Solodenko J, Staab A, Teutonico D. Open systems pharmacology community - an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences. CPT Pharmacometrics Syst Pharmacol 2019;8(12):878-882.

Türk D, Hanke N, Wolf S, Frechen S, Eissing T, Wendl T, Schwab M, Lehr T. Physiologically based pharmacokinetic models for prediction of complex CYP2C8 and OATP1B1 (SLCO1B1) drug-drug-gene interactions: a modeling network of gemfibrozil, repaglinide, pioglitazone, rifampicin, clarithromycin and itraconazole. Clin Pharmacokinet 2019;58(12):1595-1607.

Scherer N, Kurbasic A, Dings C, Mari A, Nock V, Hennige AM, Koivula RW, Laakso M, Siloaho M, McDonald TJ, Pavo I, Giordano GN, Hansen TH, Rutters F, Dekker JM, Jablonka B, Ruetten H, Pearson ER, Franks PW, Lehr T. The impact and correction of analysis delay and variability in storage temperature on the assessment of HbA1c from dried blood spots -  an IMI DIRECT Study. Int J Proteom Bioinform 2019;4(1):7-13.

Moj D, Maas H, Schaeftlein A, Hanke N, Gómez-Mantilla JD, Lehr T. A comprehensive whole-body physiologically based pharmacokinetic model of dabigatran etexilate, dabigatran and dabigatran glucuronide in healthy adults and renally impaired patients. Clin Pharmacokinet 2019;58(12):1577-1593.

Hanke N, Kunz C, Thiemann M, Fricke H, Lehr T. Translational PBPK modeling of the protein therapeutic and CD95L inhibitor asunercept to develop dose recommendations for its first use in pediatric glioblastoma patients. Pharmaceutics 2019;11(4):152.

Britz H, Hanke N, Volz AK, Spigset O, Schwab M, Eissing T, Wendl T, Frechen S, Lehr T. PBPK models for CYP1A2 DDI prediction: a modelling network of fluvoxamine, theophylline, caffeine, rifampicin and midazolam. CPT Pharmacometrics Syst Pharmacol 2019;8(5):296-307.

Ardelt MA, Fröhlich T, Martini E, Müller M, Kanitz V, Atzberger C, Cantonati P, Meßner M, Posselt L, Lehr T, Wojtyniak JG, Ulrich M, Arnold GJ, König L, Parazzoli D, Zahler S, Rothenfußer S, Mayr D, Gerbes A, Scita G, Vollmar AM, Pachmayr J. Inhibition of Cyclin-dependent kinase 5 - a strategy to improve sorafenib response in hepatocellular carcinoma therapy. Hepatology 2019;69(1):376-393.

2018

Ramharter M, Schwab M, Mombo-Ngoma G, Zoleko Manego R, Akerey-Diop D, Basra A, Mackanga J.R, Würbel H, Wojtyniak JG, Gonzalez R, Hofmann U, Geditz M, Matsiegui P.B, Kremsner P.G, Menendez C, Kerb R, Lehr T. Population pharmacokinetics of mefloquine intermittent preventive treatment for malaria in pregnancy in Gabon. Antimicrobl Agents and Chemother 2018;63(2).

Balazki P, Schaller S, Eissing T, Lehr T. A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of the SGLT inhibitors. CPT Pharmacometrics Syst Pharmacol 2018;7(12):788-797.

Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network for rifampicin, itraconazole, clarithromycin, midazolam, alfenatil and digoxin. CPT Pharmacometrics Syst Pharmacol 2018;7(10):647-659.

Mulyukov Z, Weber S, Pigeolet E, Clemens A, Lehr T, Racine A. Neovascular age-related macular degeneration - a visual acuity model of natural disease progression and ranibizumab treatment effect. CPT Pharmacometrics Syst Pharmacol 2018;7(10):660-669.

Schaefer N, Wojtyniak JG, Kroell AK, Koerbel C, Laschke MW, Lehr T, Menger MD, Maurer HH, Meyer MR, Schmidt PH. Can toxicokinetics of (synthetic) cannabinoids in pigs after pulmonary administration be upscaled to humans by allometric techniques? Biochem Pharmacol 2018;155:403-418.

Lott D, Lehr T, Dingemanse J, Krause A. Modeling tolerance development for the effect on heart rate of the selective S1P1 receptor modulator ponesimod. Clin Pharmacol Ther 2018;103(6):1083-92.

Miller R, Wojtyniak JG, Weckesser LJ, Alexander NC, Engert V, Lehr T. How to disentangle psychobiological stress reactivity and recovery: a comparison of model-based and non-compartmental analyses of cortisol concentrations. Psychoneuroendocrinology 2018;90:194-210.

Schaefer N, Moj D, Lehr T, Schmidt PH, Ramsthaler F. The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine. Int J Legal Med 2018;132(2):415-24.

Hanke N, Teifel M, Moj D, Wojtyniak JG, Britz H, Aicher B, Sindermann H, Ammer N, Lehr T. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis. Cancer Chemother Pharmacol 2018;81(2):291-304.

Scholl C, Lepper A, Lehr T, Hanke N, Schneider KL, Brockmöller J, Seufferlein T, Stingl JC. Population Nutrikinetics of green tea extract. PLoS One 2018;13(2);e0193074.

2017

Moj D, Britz H, Burhenne J, Stewart CF, Egerer G, Haefeli WE, Lehr T. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Cancer Chemother Pharmacol 2017;80(5):1013-26.

Volz AK, Krause A, Haefeli WE, Dingemanse J, Lehr T. Target-mediated drug disposition pharmacokinetic-pharmacodynamic model of bosentan and Endothelin-1. Clin Pharmacokinet 2017;56(12):1499-511.

Scherer N, Dings C, Böhm M, Laufs U, Lehr T. Alternative treatment regimens with the PCSK9 inhibitors Alirocumab and Evolocumab: a pharmacokinetic and pharmacodynamic modeling approach. J Clin Pharmacol 2017;57(7):846-54.

Lott D, Lehr T, Dingemanse J, Krause A. Impact of demographics, organ impairment, disease, formulation, and food on the pharmacokinetics of the selective S1P1 receptor modulator ponesimod based on 13 clinical studies. Clin Pharmacokinetics 2017;56(4):395-408.

Moj D, Hanke N, Britz H, Frechen S, Kanacher T, Wendl T, Haefeli WE, Lehr T. Clarithromycin, midazolam, and digoxin: application of PBPK modeling to gain new insights into drug-drug interactions and co-medication regimens. AAPS J 2017;19(1):298-312.

Titze MI, Schaaf O, Hofmann MH, Sanderson MP, Zahn SK, Quant J, Lehr T. An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor. Cancer Chemother Pharmacol 2017;79(3):545-58.

Titze MI, Frank J, Ehrhardt M, Smola S, Graf N, Lehr T. A generic viral dynamic model to systematically characterize the interaction between oncolytic virus kinetics and tumor growth. Eur J Pharm Sci 2017;97:38-46.

Lott D, Krause A, Seemayer CA, Strasser DS, Dingemanse J, Lehr T. Modeling the effect of the selective S1P1 receptor modulator ponesimod on subsets of blood lymphocytes. Pharm Res 2017;34(3):599-609.

2016

Titze MI, Schaaf O, Hofmann MH, Sanderson MP, Zahn SK, Quant J, Lehr T. A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques. Cancer Chemother Pharmacol 2016;77(6):1303-1314.

Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban S, Haefeli WE. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol 2016;65(3):483-9.

Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp FA, Wedemeyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a Phase Ib/IIa study. J Hepatol 2016;65(3):490-8.

Halton JML, Lehr T, Cronin L, Lobmeyer MT, Haertter S, Belletrutti M, Mitchell LG & others. Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study. Thromb Haemost 2016;116(3):461-471.

Lott D, Krause A, Dingemanse J, Lehr T. Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects. Eur J Pharm Sci 2016;89:83-93.

Merk H, Zhang S, Lehr T, Müller C, Ulrich M, Bibb JA, Adams RH, Bracher F, Zahler S, Vollmar AM, Liebl J. Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis. Oncotarget 2016;7(5):6088-104.

Schaefer N, Wojtyniak JG, Kettner M, Schlote J, Laschke MW, Ewald AH, Lehr T, Menger MD, Maurer HH, Schmidt PH. Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology. Toxicol Lett 2016;253:7-16.

Schneider LS, Ulrich M, Lehr T, Menche D, Müller R, von Schwarzenberg K. MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition. Mol Oncol 2016;10(7):1054-1062.

2015

Schneider LS, von Schwarzenberg K, Lehr T, Ulrich M, Kubisch-Dohmen R, Liebl J, Trauner D, Menche D, Vollmar AM. Vacuolar-ATPase inhibition blocks iron metabolism to mediate therapeutic effects in breast cancer. Cancer Res 2015;75(14):2863-74.

Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, Brandl L, Kirchner T, Zahler S, Gerbes AL, Vollmar AM. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma - a novel therapeutic approach. J Hepatol 2015;63(1):102-13.

Bortolussi L, Krueger T, Lehr T, Wolf V. Rule-based modelling and simulation of drug-administration policies. Conference Proceedings 2015 Spring Simulation Multi-Conference (SpringSim'15).

2014

Gomez-Mantilla JD, Schaefer UF, Casabo VG, Lehr T, Lehr CM. Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations. AAPS J 2014;16(4):791-801.

Reilly PA*, Lehr T*, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmitz G, Wang S, Wallentin L. The effect of dabigatran plasma concentrations and patients characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients in the RE-LY Trial. J Am Coll Cardiol 2014;63(4):321-328; *co-first authors.

2013

Haug KG, Staab A, Dansirikul C, Lehr T. A semi-physiological model of Amyloid-β biosynthesis and clearance in human cerebrospinal fluid: a tool for Alzheimer's disease research and drug development. J Clin Pharmacol 2013;53(7):691-698. 

Liesenfeld KH, Staab A, Härtter S, Formella S, Clemens A, Lehr T. Pharmacometric characterization of dabigatran hemodialysis. Clin Pharmacokinet 2013;52:453-462.

Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013;127(13):1404-12.

Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, Neumayer HH, Liesenfeld KH, Lehr T, Härtter S, Friedman J, Peters H, Clemens A. Effective elimination of dabigatran by haemodialysis: a phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013;109(4):596-605. 

2012

Lehr T, Haertter S, Liesenfeld KH, Staab A, Clemens A, Reilly PA, Friedman J. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 2012;52(9):1373-8.  

Van De Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Härtter S, Harper R, Kappetein AP, Lehr T, Mack MJ, Noack H, Eikelboom JW. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 2012;163(6):931-937.

Dansirikul C, Lehr T, Liesenfeld KH, Haertter S, Staab A. A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. Thromb Haemost 2012;107(4):775-85.

Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: Reply to a rebuttal. J Thromb Haemost 2012;10(3):502-4.

Clemens A, Haertter S, Friedman J, Brueckmann M, Stangier J, Van Ryn J, Lehr T. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: A pharmacokinetic justification. Curr Med Res Opin 2012;28(2):195-201.

2011

Lehr T, Yuan J, Hall D, Zimdahl-Gelling H, Schaefer HG, Staab A, MacGregor TR, Jayadev S. Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. Pharmacogenet Genomics 2011;21(11):721-30.

Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011;9(11):2168-75.

Lehr T, Yuan J, Zeumer D, Jayadev S, Ritchie MD. Rule based classifier for the analysis of gene-gene and gene-environment interactions in genetic association studies. BioData Mining 2011;4(1).

2010

Lehr T, Schaefer HG, Staab A. Integration of high-throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modeling. Pharmacogenet Genomics 2010;20(7):442-50.

Lehr T, Narbe R, Jöns O, Kloft C, Staab A. Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats. J Vet Pharmacol Ther 2010;33(3):277-86.

Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C. Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine. AAPS Journal 2010;12(2):117-29.

Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Clin Pharmacokinet 2010;49(1):53-66.

2007-2009

Lehr T, Staab A, Tillmann C, Trommeshauser D, Schaefer HG, Kloft C. A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. Clin Pharmacokinet 2009;48(8):529-42.

Lehr T, Staab A, Tillmann C, Nielsen EØ, Trommeshauser D, Schaefer HG, Kloft C. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: A pharmacokinetic-pharmacodynamic modelling approach. Br J Pharmacol 2008;153(1):164-74.

Lehr T, Staab A, Tillmann C, Trommeshauser D, Raschig A, Schaefer HG, Kloft C. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. Br J Clin Pharmacol 2007;64(1):36-48.